Overview
This program addresses the lack of awareness of methamphetamine associated pulmonary arterial hypertension (METH-PAH), including its epidemiology, clinical characteristics, and known pathophysiology; improving early detection, screening, and diagnosis of METH-PAH; and integrating approaches to the treatment of METH-PAH that seek to address both the PAH and underlying substance use disorder.
This course is brought to you in partnership with our sister company freeCME. Clicking the Add to Cart button will take you to the freeCME website where you can access this course for FREE.
Goals and Learning Outcomes
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology and clinical characteristics of methamphetamine-associated pulmonary arterial hypertension (MA-PAH)
- Explain the current understanding of the pathophysiological mechanisms linking methamphetamine use to PAH development
- Identify key screening and diagnostic approaches for early detection of PAH in methamphetamine users
- Summarize a comprehensive approach to the treatment of MA-PAH that seeks to integrate pharmacotherapy for PAH and substance use disorder management
Faculty
Vinicio de Jesus Perez, MD
Associate Dean of Stanford MD Admissions and Professor of Medicine (PACCM)
Stanford Medicine
Palo Alto, CA
Steven Shoptaw, PhD
George F Kneller Term Chair in Family Medicine
Vice Chair of Research and Professor in Family Medicine
David Geffen School of Medicine
University of California, Los Angeles
Julio Meza, MD
Health Sciences Assistant Clinical Professor Dept. Family Medicine
Addiction Medicine Fellowship Program Director
David Geffen School of Medicine
University of California, Los Angeles
Course Details
FREECME2025-11-03
Accreditations
This course is being provided by a Relias LLC strategic partner. Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.